Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | IDH1 R132H |
Therapy | Elimusertib + Olaparib |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
IDH1 R132H | Advanced Solid Tumor | sensitive | Elimusertib + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Lynparza (olaparib) and Elimusertib (BAY1895344) resulted in a greater decrease in cell survival compared to BAY1895344 alone in cells expressing IDH1 R132H in culture (PMID: 34027408). | 34027408 |
PubMed Id | Reference Title | Details |
---|---|---|
(34027408) | Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors. | Full reference... |